Research Topics
| Nicole D UrbanSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancerNicole Urban
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, P O Box 19024, Seattle, WA 98109, USA
Cancer Epidemiol Biomarkers Prev 21:2087-94. 2012..Human epididymis protein 4 (HE4) is approved for clinical use with CA125 to predict epithelial ovarian cancer in women with a pelvic mass or in remission after chemotherapy. Previously reported reference ranges for HE4 are inconsistent...- Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discoveryNathalie Scholler
Center for Research on Early Detection and Cure of Ovarian Cancer, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
J Transl Med 6:41. 2008..We developed a novel technology that permits us to isolate recombinant antibodies directed against the potential serum biomarkers, to facilitate the further development of affinity reagents necessary to construct diagnostic tests... 
Current and future developments in screening for ovarian cancerNicole Urban
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230 Seattle, WA 98109, USA
Womens Health (Lond Engl) 2:733-42. 2006....- Ovarian cancer screeningNicole Urban
Cancer Prevention Research Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, MP 900, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
Hematol Oncol Clin North Am 17:989-1005, ix. 2003..Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods... - Computer-assisted mammography feedback program (CAMFP) an electronic tool for continuing medical educationNicole Urban
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M2 B230, Seattle, WA 98109 1024, USA
Acad Radiol 14:1036-42. 2007..Our goal was to develop and evaluate software to support a computer assisted mammography feedback program (CAMFP) to be used for continuing medical education (CME)... - Designing early detection programs for ovarian cancerN Urban
Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Ann Oncol 22:viii6-viii18. 2011..Incorporation of symptoms in a screening strategy that includes CA125 and HE4 may warrant further research... - Potential role of HE4 in multimodal screening for epithelial ovarian cancerNicole Urban
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 103:1630-4. 2011..03). Serum HE4 levels were found to increase with age and smoking status, suggesting that a longitudinal algorithm might improve its performance... - Developing measures of mammography performanceNicole Urban
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Med Care 40:III86-8. 2002 - Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkersAlicia H Sato
Fred Hutchinson Cancer Research Center, Seattle, WA 90109, USA
Cancer Biomark 2:151-62. 2006.... - Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyGarnet L Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, PO Box 19024, M3 A410, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 102:26-38. 2010..Except for CA125, their behavior in the prediagnostic period has not been evaluated... 
Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancersSheng Pan
Department of Pathology, University of Washington, Seattle, Washington, USA
OMICS 13:345-54. 2009..Our results suggest that chemotherapy response may be determined by multiple and complex system properties involving extracellular-matrix, cell adhesion and junction proteins...- Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125Chirag A Shah
University of Washington, Seattle, WA 98195, USA
Cancer Epidemiol Biomarkers Prev 18:1365-72. 2009..To evaluate the effect of ovarian cancer risk on the performance of the serum biomarkers mesothelin, human epididymis protein 4 (HE4), and CA125... - Use of high density antibody arrays to validate and discover cancer serum biomarkersChristian M Loch
Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Mol Oncol 1:313-20. 2007..We demonstrate its performance by showing that known tumor markers behave as expected. We also identify several promising biomarkers from a candidate list and generate hypotheses to support new discovery studies... - Use of a single-chain antibody library for ovarian cancer biomarker discoveryARTURO B RAMIREZ
Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Mol Cell Proteomics 9:1449-60. 2010..Thus, our use of recombinant antibody microarrays for unbiased discovery found targets for ovarian cancer detection in multiple sample sets, supporting their further study for disease diagnosis... - Development of an ovarian cancer symptom index: possibilities for earlier detectionBarbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98196 6460, USA
Cancer 109:221-7. 2007..Currently, screening for ovarian cancer is not recommended for the general population. Targeting women with specific symptoms for screening has been evaluated only recently, because it was believed that symptoms had limited specificity... - Circulating microRNAs as stable blood-based markers for cancer detectionPatrick S Mitchell
Divisions of Human Biology, Clinical Research, and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Proc Natl Acad Sci U S A 105:10513-8. 2008..Our results establish the measurement of tumor-derived miRNAs in serum or plasma as an important approach for the blood-based detection of human cancer... - Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachmentLindsay Bergan
Molecular Diagnositics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Cancer Lett 255:263-74. 2007..Anti-mesothelin Bbs derived from high affinity yeast-display scFv detected both membrane-bound and soluble mesothelins and inhibited CA125/mesothelin-dependent cell attachment... - The HE4 (WFDC2) protein is a biomarker for ovarian carcinomaIngegerd Hellstrom
Pacific Northwest Research Institute, Seattle, Washington 98122, USA
Cancer Res 63:3695-700. 2003..However, the HE4 assay may have an advantage over the CA125 assay in that it is less frequently positive in patients with nonmalignant disease... - Bead-based ELISA for validation of ovarian cancer early detection markersNathalie Scholler
Translational Outcomes Research Laboratory, Fred Hutchinson Cancer Research Center, Public Health Sciences, and Harborview Medical Center, University of Washington, Seattle, Washington, USA
Clin Cancer Res 12:2117-24. 2006.... - Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancerKimberly A Lowe
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Cancer Epidemiol Biomarkers Prev 17:2480-7. 2008..To evaluate if serum levels of candidate ovarian cancer biomarkers vary with individual characteristics of healthy women who are likely candidates for an ovarian cancer screening program... - Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification TrialAnne McTiernan
Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA 98019, USA
Am J Clin Nutr 89:1864-76. 2009..The effects of dietary changes on osteoporosis, low bone density, and frequent falls are unestablished... - No effect of aspirin on mammographic density in a randomized controlled clinical trialAnne McTiernan
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Cancer Epidemiol Biomarkers Prev 18:1524-30. 2009.... - The temporal stability of the Symptom Index among women at high-risk for ovarian cancerKimberly A Lowe
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Gynecol Oncol 114:225-30. 2009..To evaluate the temporal stability of self-reported symptoms known to be associated with ovarian cancer... - Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trialChris P Miller
Department of Medicine Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington 98109, USA
Stem Cells 27:2353-61. 2009..Our results provide a framework for exploring the relationship between Epo, cancer progression, and survival using archival tumors from other Phase III clinical trials... - Use of a Symptom Index, CA125, and HE4 to predict ovarian cancerM Robyn Andersen
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Gynecol Oncol 116:378-83. 2010..Prior studies suggest that combining the Symptom Index (SI) with a serum HE4 test or a CA125 test may improve prediction of ovarian cancer. However, these three tests have not been evaluated in combination... - The case for early detectionRuth Etzioni
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
Nat Rev Cancer 3:243-52. 2003..been revitalized by the advent of novel molecular technologies that can identify cellular changes at the level of the genome or proteome, but how can we harness these new technologies to develop effective and practical screening tests?.. - Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detectionMichel Schummer
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 5:e9122. 2010.... - Breast cancer genomics: normal tissue and cancer markersMichel Schummer
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Ann N Y Acad Sci 1210:78-85. 2010..Here we report the identification of potential breast cancer markers, including some that are overexpressed in aggressive disease... - Combining a symptoms index with CA 125 to improve detection of ovarian cancerM Robyn Andersen
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Cancer 113:484-9. 2008.... - Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersWataru Sakai
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Nature 451:1116-20. 2008..Our results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy... - Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancerM Robyn Andersen
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Am J Clin Oncol 28:17-20. 2005..This information can be used to identify patients eligible for intervention trials... - A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarkerMartin W McIntosh
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue MP 900, Seattle, WA 98109, USA
Biostatistics 4:27-40. 2003..Our method was specifically developed for use in screening for cancer with a new biomarker, but it is appropriate whenever the pre-clinical behavior of the disease and/or biomarker is uncertain... - Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17qBrad Stone
Benaroya Research Institute at Virginia Mason Research Center, Seattle, WA 98101 2795, USA
Int J Cancer 104:73-84. 2003..Thus, these abnormal expression patterns combined with the endogenous immune response suggests that these antigens represent potential targets for immunotherapy... - Analysis of the cost-effectiveness of mammography promotion by volunteers in rural communitiesM Robyn Andersen
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Health Educ Behav 29:755-70. 2002..Exploratory analyses suggest that the most cost-effective method of promoting mammography use may vary with the target population... - Assertiveness with physicians is related to women's perceived roles in the medical encounterM Robyn Andersen
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
Women Health 42:15-33. 2005..Data are also presented on the development of a scale designed to assess assertiveness with physicians for use in studies of medical care... - Costs and cost-effectiveness of a clinical intervention to increase mammography utilization in an inner city public health hospitalBeti Thompson
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP 702, Seattle, Washington 98109 1024, USA
Prev Med 35:87-96. 2002..Studies have demonstrated the cost-effectiveness of screening women for breast cancer; however, the cost-effectiveness of strategies to motivate women to receive breast cancer screening has been less well studied... - Worry about ovarian cancer risk and use of screening by high-risk women: how you recruit affects what you findM Robyn Andersen
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Am J Med Genet A 129:130-5. 2004..High-risk women recruited via mass mailing were less likely than those recruited via physicians or affected relatives to report either worry about their risk or use of ovarian cancer screening tests... - Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discoveryNathalie Scholler
Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
Cancer Lett 247:130-6. 2007..We finally demonstrated that a mesothelin chimeric protein and anti-CA125 antibodies block CA125/mesothelin-dependent cell attachment... - Method for generation of in vivo biotinylated recombinant antibodies by yeast matingNathalie Scholler
Translational Outcomes Research Group, Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
J Immunol Methods 317:132-43. 2006..8 x 10(-9) M and K(d)=5.1 x 10(-9) M before and after Ni-purification respectively. Thus, yeast mating permits cost-effective generation of biotinylated recombinant antibodies of high affinity... - Examining the cost-effectiveness of cancer screening promotionM Robyn Andersen
Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98102 1024, USA
Cancer 101:1229-38. 2004..The authors showed that CEA can be a valuable tool for understanding the merits of health promotion interventions and that CEA is particularly valuable in identifying screening strategies that might be promoted most cost-effectively... - Changes in cancer worry associated with participation in ovarian cancer screeningM Robyn Andersen
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Psychooncology 16:814-20. 2007..Further research will be required to examine the possibility that screening reduces worry when women receive only normal, presumably reassuring, results... - Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinomaMartin W McIntosh
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Clin Cancer Res 13:4422-8. 2007..The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125... - Effects of blood collection conditions on ovarian cancer serum markersJason D Thorpe
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 2:e1281. 2007..By measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these effects to bias validation studies... - Generating longitudinal screening algorithms using novel biomarkers for diseaseMartin W McIntosh
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Cancer Epidemiol Biomarkers Prev 11:159-66. 2002..The algorithm is particularly useful when screening with a new marker of which the behavior in the preclinical period is not well known... - Compliance of average- and intermediate-risk women to semiannual ovarian cancer screeningCharles W Drescher
Swedish Hospital and Medical Center, 1101 Madison Street, Suite 1500, Seattle, WA 98104, USA
Cancer Epidemiol Biomarkers Prev 13:600-6. 2004.... - An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcriptionEmily C Knouf
Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Nucleic Acids Res 40:499-510. 2012..This study delineates an integrative approach that can be applied to discover transcriptional regulatory mechanisms in other biological settings where analogous genomic data are available... - Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA librariesStacia K Wyman
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 4:e5311. 2009..A critical step toward these goals is to establish a comprehensive view of miRNAs expressed in epithelial ovarian cancer tissues as well as in normal ovarian surface epithelial cells... - Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discoverySharon J Pitteri
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 4:e7916. 2009..The goal of this work is to evaluate the utility of an integrative strategy using these two approaches for biomarker discovery... - Use of the American College of Radiology BI-RADS guidelines by community radiologists: concordance of assessments and recommendations assigned to screening mammogramsConstance Lehman
Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave, G4-830, Seattle, WA 98109-1023, USA
AJR Am J Roentgenol 179:15-20. 2002..Continued efforts to educate radiologists about the use of BI-RADS and to clarify BI-RADS terms would promote maximum consistency in this use of this reporting method... - Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transitionAusra Bendoraite
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Gynecol Oncol 116:117-25. 2010..Our objective was to characterize the expression and function of the miR-200 family of microRNAs (miRNA) in ovarian carcinogenesis... - Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammographyStephen H Taplin
Center for Health Studies, Group Health Cooperative of Puget Sound, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, USA
Radiology 222:529-35. 2002..To examine how frequently Breast Imaging Reporting and Data System (BI-RADS) mammographic screening assessments were associated with expected clinical management recommendations... - Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancerVivian Goodell
Center for Translational Medicine in Women s Health, Tumor Vaccine Group, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
J Clin Oncol 24:762-8. 2006..We questioned whether antibody immunity specific for ovarian cancer tumor antigens would predict disease outcome. We evaluated humoral immune responses against ovarian cancer antigens p53, HER-2/neu, and topoisomerase IIalpha... - Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trialLesley F Tinker
Women s Health Initiative, Fred Hutchinson Cancer Research Center, PO Box 19024, Mail Stop M3 A410, Seattle, WA 98109, USA
Arch Intern Med 168:1500-11. 2008..This study was undertaken to assess the effects of a low-fat dietary pattern on incidence of treated diabetes among generally healthy postmenopausal women... - Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levelsJennifer J Stewart
The Institute for Systems Biology, Seattle, Washington 98103, USA
Mol Cell Proteomics 5:433-43. 2006..Several proteins may be involved in modulating response to cisplatin and have potential as markers of treatment response or treatment targets... - A mouse to human search for plasma proteome changes associated with pancreatic tumor developmentVitor M Faca
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS Med 5:e123. 2008.... - Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenovirusesRobert Strauss
Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA
Cancer Res 69:5115-25. 2009..Our study provides a venue for improved virotherapy of cancer as well as new insights into cancer cell biology... - DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinomaQinghua Feng
Department of Pathology, School of Medicine, University of Washington, Seattle, Washington, USA
Gynecol Oncol 111:320-9. 2008.... - Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistanceElizabeth M Swisher
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
Cancer Res 68:2581-6. 2008..Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors... - 10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill
Barts and the London Queen Mary's School of Medicine and Dentistry, UK
Cancer Res 66:2904-6. 2006....
Research Grants
- Modeling ovarian cancer screening for CEANicole Urban; Fiscal Year: 2005..Ultimately, an enhanced microsimulation model that incorporates new developments, innovations of the future as well as those we recognize today, will help guide policy and research investment decisions. ..
- Prevention of Ovarian Cancer in Women Participating in MammographyNicole Urban; Fiscal Year: 2007....